Celldex Therapeutics, Inc.
CLDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7,020 | $6,883 | $2,357 | $4,651 |
| % Growth | 2% | 192% | -49.3% | – |
| Cost of Goods Sold | $163,550 | $118,011 | $82,258 | $53,311 |
| Gross Profit | -$156,530 | -$111,128 | -$79,901 | -$48,660 |
| % Margin | -2,229.8% | -1,614.5% | -3,389.9% | -1,046.2% |
| R&D Expenses | $163,550 | $118,011 | $82,258 | $56,811 |
| G&A Expenses | $38,548 | $30,914 | $27,195 | $20,488 |
| SG&A Expenses | $38,548 | $30,914 | $27,195 | $20,488 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$163,550 | -$105,511 | -$74,120 | -$54,716 |
| Operating Expenses | $38,548 | $43,414 | $35,333 | $22,583 |
| Operating Income | -$195,078 | -$154,542 | -$115,234 | -$71,243 |
| % Margin | -2,778.9% | -2,245.3% | -4,889% | -1,531.8% |
| Other Income/Exp. Net | $37,215 | $13,113 | $2,909 | $959 |
| Pre-Tax Income | -$157,863 | -$141,429 | -$112,325 | -$70,284 |
| Tax Expense | $0 | $0 | $0 | $227 |
| Net Income | -$157,863 | -$141,429 | -$112,325 | -$70,511 |
| % Margin | -2,248.8% | -2,054.8% | -4,765.6% | -1,516% |
| EPS | -2.45 | -2.92 | -2.4 | -1.64 |
| % Growth | 16.1% | -21.7% | -46.3% | – |
| EPS Diluted | -2.45 | -2.92 | -2.4 | -1.64 |
| Weighted Avg Shares Out | 64,395 | 48,449 | 46,888 | 42,870 |
| Weighted Avg Shares Out Dil | 64,395 | 48,449 | 46,888 | 42,870 |
| Supplemental Information | – | – | – | – |
| Interest Income | $37,215 | $13,113 | $2,909 | $505 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3,177 | $3,008 | $2,896 | $3,068 |
| EBITDA | -$191,901 | -$139,034 | -$104,200 | -$66,080 |
| % Margin | -2,733.6% | -2,020% | -4,420.9% | -1,420.8% |